Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine Switch Study in Virologically Suppressed HIV-1 Infected Children
NCT04012931Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Jul 2019; status: completed.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04012931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04012931.